Business
Continued growth in revenue and operating profit
Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9 million in the year-earlier period. Growth was driven primarily by sales of products related to the NC platform, reflecting increased activity levels for customers with ongoing clinical trials and approved therapies. The Q3 performance reflected continued growth in sales of both instruments, consumab
About this update from Chemometec A/s
[{"type":"image","alt":"Chemometec A/S","displaySize":"","headline":null,"caption":"Chemometec A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/fb7f647883e7e37b706ad984bdd29198"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4NfO27rPrtZqtUz4kabB5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fb7f647883e7e37b706ad984bdd29198","width":210,"height":87}},"lazy":false},{"type":"text","content":"Trading statement for Q3 2024/25 (1 January - 31 March 2025)","length":60,"tagName":"p"},{"type":"text","content":"Continued growth in revenue and operating profit","length":48,"tagName":"p"},{"type":"text","content":"Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9 million in the year-earlier period. Growth was driven primarily by sales of products related to the NC platform, reflecting increased activity levels for customers with ongoing clinical trials and approved therapies. The Q3 performance reflected continued growth in sales of both instruments, consumables and services. The launch of the new XcytoMatic products is still proceeding as planned, and the number of customer validations in progress has increased significantly. Moreover, the new NC-203 instruments achieved their first sale to a customer in the third quarter.","length":660,"tagName":"p"},{"type":"text","content":"EBITDA increased to DKK 63.4 million in the third quarter, taking the EBITDA margin to 51%.","length":91,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:151.2px;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"2024/25","length":7,"tagName":"p","attribs":{}}]},{"style":"width:18.94px;border-bottom:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"colspan":"2","style":"width:217.4px;border-bottom:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Q3","length":2,"tagName":"p","attribs":{}}]},{"style":"width:18.87px;text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName...